Impact of different welding techniques on biological effect markers in exhaled breath condensate of 58 mild steel welders.

Total mass and composition of welding fumes are predominantly dependent on the welding technique and welding wire applied. The objective of this study was to investigate the impact of welding techniques on biological effect markers in exhaled breath condensate (EBC) of 58 healthy welders. The welding techniques applied were gas metal arc welding with solid wire (GMAW) (n=29) or flux cored wire (FCAW) (n=29). Welding fume particles were collected with personal samplers in the breathing zone inside the helmets. Levels of leukotriene B(4) (LTB(4)), prostaglandin E(2) (PGE(2)), and 8-isoprostane (8-iso-PGF(2α)) were measured with immunoassay kits and the EBC pH was measured after deaeration. Significantly higher 8-iso-PGF(2α) concentrations and a less acid pH were detected in EBC of welders using the FCAW than in EBC of welders using the GMAW technique. The lowest LTB(4) concentrations were measured in nonsmoking welders applying a solid wire. No significant influences were found in EBC concentrations of PGE(2) based upon smoking status or type of welding technique. This study suggests an enhanced irritative effect in the lower airways of mild steel welders due to the application of FCAW compared to GMAW, most likely associated with a higher emission of welding fumes.

Changes in the tumor microenvironment during low-dose-rate permanent seed implantation iodine-125 brachytherapy.

PURPOSE: There is a lack of data regarding how the tumor microenvironment (e.g., perfusion and oxygen partial pressure [pO2]) changes in response to low-dose-rate (LDR) brachytherapy. This may be why some clinical issues remain unresolved, such as the appropriate use of adjuvant external beam radiation therapy (EBRT). The purpose of this work was to obtain some basic preclinical data on how the tumor microenvironment evolves in response to LDR brachytherapy. METHODS AND MATERIALS: In an experimental mouse tumor, pO2 (measured by electron paramagnetic resonance) and perfusion (measured by dynamic contrast-enhanced magnetic resonance imaging) were monitored as a function of time (0-6 days) and distance (0-2 mm and 2-4 mm) from an implanted 0.5 mCi iodine-125 brachytherapy seed. RESULTS: For most of the experiments, including controls, tumors remained hypoxic at all times. At distances of 2-4 mm from radioactive seeds ( approximately 1.5 Gy/day), however, there was an early, significant increase in pO2 within 24 h. The pO2 in that region remained elevated through Day 3. Additionally, the perfusion in that region was significantly higher than for controls starting at Day 3. CONCLUSION: It may be advantageous to give adjuvant EBRT shortly (approximately 1 to 2 days) after commencement of clinical LDR brachytherapy, when the pO2 in the spatial regions between seeds should be elevated. If chemotherapy is given adjuvantly, it may best be administered just a little later (approximately 3 or 4 days) after the start of LDR brachytherapy, when perfusion should be elevated.

Optimization of a breast implant in Brachytherapy PDR: validation with Monte Carlo simulation and measurements with TLDs and GafChromic films.

BACKGROUND AND PURPOSE: The calculation of the dose distribution of Brachytherapy breast implant has been carried out in accordance with the Paris System (PS) in the majority of the radiotherapy departments in Europe. PDR (Pulsed Dose Rate) has lead to an improvement of the treatment procedure, optimization tools, however, allow an improvement of the treatment technique. The goal of this study was to perform a dosimetric verification of an optimized seven needles implant and to try to decrease the active length while preserving the same treatment volume. This corresponds to a ratio "treated length/active length" (L(t)/L(a)) that tends towards 1. MATERIAL AND METHODS: A dosimetry phantom was made of polystyrene, capable of receiving the implant, TLDs (LiF100 1mm(3) micro cubes) and films (GafChromic MD 55-2). Dose distributions for one source position and for the implant in conformity with the PS were calculated, utilizing version 14.2 of the Plato TPS (Nucletron); the remote afterloading system was a microSelectron-PDR (Nucletron). MCNP (Monte Carlo N-Particles transport) modeling was used for various configurations to evaluate the influence of the composition of the medium, of the presence of the needles and the lack of scatter. RESULTS: The benefit of the optimization was shown by the determination of a L(t)/L(a) factor of 1.05 instead of 0.7 for the standard PS. The dose distributions calculated by Plato are in agreement with TLD and film measurements for the optimization and the PS (<5%). The TPS results were confirmed by MC calculation as well as by measurements. MC calculations also showed that only the lack of scatter had a significant influence on the dose received by the skin (20%) CONCLUSIONS: The optimization brings a significant benefit in protecting the skin and in homogeneity of the dose distribution in the treated volume. Through MC simulation, this work made it possible to update a parameter significantly influencing dose distribution calculations: the lack of scattering.